Identification of angular naphthopyrones from the Philippine echinoderm Comanthus species as inhibitors of the NF-κB

Yvonni Chovolou1, Sherif Saeed Ebada, Wim Wätjen

  • 1Heinrich-Heine-Universität, Institute of Toxicology, P.O. Box 101007, 40001 Düsseldorf, Germany. chovolou@uni-duesseldorf.de

Insights

Marine echinoderms yielded comaparvin, a new inhibitor of the nuclear factor kappa-B (NF-κB) pathway. This compound targets proteasome activity and IκB phosphorylation, offering a novel strategy for cancer therapy.

Area of Science:

  • Marine natural products chemistry
  • Molecular oncology
  • Signal transduction

Background:

  • The nuclear factor kappa-B (NF-κB) pathway is crucial in cellular processes and frequently dysregulated in cancer.
  • Inhibiting NF-κB is a promising anti-cancer strategy, driving the search for novel therapeutic agents.
  • Marine organisms are a rich source of structurally diverse compounds with potential biological activities.

Purpose of the Study:

  • To identify novel NF-κB inhibitors from marine sources.
  • To elucidate the mechanism of action of identified compounds.
  • To evaluate their potential in cancer treatment.

Main Methods:

  • Bioassay-guided fractionation of a marine echinoderm (Comanthus sp.) extract.
  • Isolation and structural elucidation of ten compounds (anthraquinones and naphthopyrones).
  • In vitro assays to assess NF-κB inhibition, proteasomal activity, IκB phosphorylation, and apoptosis induction in cancer cells.

Main Results:

  • Two naphthopyrones, comaparvin and 6-methoxycomaparvin, showed significant NF-κB inhibitory activity.
  • Comaparvin (50-100μM) inhibited proteasomal activity and IκB phosphorylation, blocking NF-κB nuclear translocation.
  • Comaparvin sensitized cancer cells to TNF-α-induced apoptosis and downregulated protective NF-κB target genes.

Conclusions:

  • Comaparvin, isolated from Comanthus sp., is a novel NF-κB signaling pathway inhibitor.
  • Its mechanism involves targeting proteasome function and IκB phosphorylation, likely via IKKβ inhibition.
  • Comaparvin demonstrates potential as an anti-cancer agent by modulating key oncogenic pathways.